2014年-普华永道全球_Asia-Pacific_Health_Industries_Newsletter_-_December_2104_16页_1mb

报告摘要

Asia-Pacific Health Industries Newsletter Summary (Issue 12, December 2014)

Core Content

This issue of the Asia-Pacific Health Industries Newsletter provides an overview of key developments in the healthcare industry across the region, focusing on MedTech, Public Private Partnerships (PPPs), Compliance, M&A, and Taxation. The newsletter is produced by PwC industry specialists and aims to keep healthcare companies and institutions informed about the latest trends and regulatory changes.

Main Topics and Key Points

1. MedTech in China

Market Growth: The Chinese MedTech market is experiencing rapid growth, with a projected value of US$50 billion by 2017, reflecting a ~20% CAGR from 2013.
Key Sub-segments: Diagnostic imaging (38%), consumables (16%), and patient aids (15%) are the top segments.
Regulatory Environment: MedTech regulations in China are evolving, with new classifications based on risk levels (Class I, II, III) and stricter requirements for clinical trials.
Government Role: The government plays a significant role in procurement and regulation, emphasizing tendering processes and healthcare reform.
Healthcare Reform: The government is expanding basic medical insurance coverage and increasing healthcare expenditure to ~6% of GDP. This reform is shifting the focus from consumables to service-based revenue in hospitals.
Compliance Challenges: The "Nine Prohibitions" continue to be enforced, targeting unethical practices such as linking HCP incomes to drug sales, accepting kickbacks, and illegal patient payments.

2. Public Private Partnerships (PPPs) in India

Healthcare Access: India aims for universal healthcare, but faces challenges due to low healthcare investment (3.5% of GDP) and limited infrastructure.
Private Sector Involvement: Private spending is significantly higher than public spending, making PPPs essential for meeting healthcare demand.
PPP Models: Lighter PPP formats, such as diagnostics and dialysis services, are more successful than complex hospital PPPs.
Regulatory Gaps: The slow growth of PPPs is attributed to lack of regulatory clarity and sector-specific guidelines.
PwC's Role: PwC has been involved in several high-profile PPP projects, including a multi-specialty tertiary care hospital initiative.

3. Compliance in Australia

Transparency Reporting: The Sunshine Act and Medicines Australia draft Code of Conduct require reporting of payments and transfers of value to HCPs.
Privacy Concerns: Consent is a critical issue, with the possibility of post-payment withdrawal.
Regulatory Changes: The ACCC granted interim authorization for Edition 17 of the Code to continue until a final decision in Q1 2015.
Implications: Companies must update stakeholder communication plans, data collection protocols, and reporting systems to comply with the new regime.

4. M&A in Taiwan

International Tie-ups: M&A activity is increasing, with foreign companies seeking to expand their presence in Asia, particularly in China.
Notable Deals:
- Alvogen acquired 67% of Lotus Pharmaceutical for US$200 million, aiming to enhance its Asia market presence.
- Alvogen also acquired Dream Pharma in South Korea for US$187 million.
- Swissray acquired Norland bone densitometry to expand its healthcare offerings.
Government Support: The Taiwan Government supports medical technology development, especially in digital imaging systems.

5. Taxation Developments

Australia: The ATO introduced reconstruction provisions in new Transfer Pricing laws, requiring self-assessment and commercial rationale documentation.
Singapore: New transfer pricing documentation requirements are being proposed, indicating a shift towards more transparent and robust tax compliance.

6. Integrated Care Campaign in Australia

Campaign Focus: Aimed at improving quality of care through integrated care models.
Outcomes: Highlighted the importance of systemic approaches to healthcare delivery.

Key Information

China's MedTech Market: Expected to grow significantly, driven by aging population, increased healthcare access, and rising demand for medical devices.
India's Healthcare Challenges: High burden of non-communicable diseases, inadequate infrastructure, and limited insurance coverage.
Australia's Compliance Trends: Transparency reporting is becoming a regulatory norm, with implications for data management and consent processes.
Taiwan's M&A Trends: Foreign investment is on the rise, with a focus on Asia market expansion and technology enhancement.
Tax Reforms: Both Australia and Singapore are introducing more stringent transfer pricing regulations, affecting international business operations.

Conclusion

The Asia-Pacific healthcare landscape is dynamic, with regulatory changes, market expansion, and compliance requirements shaping the environment for pharmaceutical, biotechnology, medical device, and diagnostic companies. PwC's insights and advisory services are crucial for navigating these complexities and ensuring sustainable growth and operational efficiency.